Sernex has launched a second Phase I clinical trial of a potential cancer drug, this time targeting hematological malignancies.
Hematological malignancies affect blood, bone marrow and lymph nodes.
The other clinical trial for the Serenex compound, called SNX-5422, targets solid tumors.
The compound was discovered using Serenex’s proprietary technology platform. SNX-544 is what Serenex calls a heat shock protein inhibitor known as Hsp90. SNX-5422 is designed to inhibit Hsp90 that “chaperons” proteins found to be necessary in cancer cell survival and growth.
“The hematology trial will enable us to take a closer look at biomarkers and early signals of anti-tumor activity in patients fighting hematological cancers,” said Serenex Chief Executive Officer Richard Kent.
Serenex, which closed on $26 million in venture financing in June, has two compounds undergoing trials.
SNX-1012 is in Phase II clinical trial. It is designed to help combat inflammation and ulceration in the mouths and digestive tracts of patients receiving chemotherapy and radiation. Serenex licensed the product in 2005.
Serenex Launches Second Clinical Trial of Potential Cancer Drug
Copyright 2007 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
-
- PC makers may face a legal challenge in ‘Green Dam’ battle from U.S. firm
Jul. 3, 2009 - As Nortel’s final demise nears, what blame should its board shoulder?
Jul. 3, 2009 - Climate change and the economy: Public policies like ‘cap and trade’ and a carbon tax could have big impacts on our wallets.
Jul. 3, 2009 - 20/20: Surgery can let you see like a child again
Jul. 3, 2009 |
- CDC: US swine flu cases rise to nearly 34,000
Jul. 3, 2009
- PC makers may face a legal challenge in ‘Green Dam’ battle from U.S. firm
-
- RTP-based Metabolon raises another $1 million in venture capital
Jul. 2, 2009 - NanoCor Therapeutics raises $2.5M
Jul. 1, 2009 - Despite three IPOs, venture-backed exits drop to trickle in second quarter
Jul. 1, 2009 - Seeking investors? Be sure to find the right angel partners
Jul. 1, 2009 - Georgia Research Alliance venture fund closes on $18.75 million
Jun. 29, 2009
- RTP-based Metabolon raises another $1 million in venture capital
More from wrallocaltechwire.com
Market Watch
advertisement


